Astragaloside IV improved oxidative stress-mediated endothelial dysfunction relevant to cardiovascular diseases through several mechanisms: preventing the uncoupling of endothelial nitric oxide synthase (eNOS), increasing eNOS and nitric oxide (NO), and enhancing several activating enzymes to activate the antioxidant system [70]. Here, NOS3 is linked to endothelial dysfunction.